Despite their young age, women with polycystic ovary syndrome (PCOS) have increased cardiovascular risk. Besides normal concentrations of low-density lipoprotein (LDL) cholesterol, dyslipidemia is very common and includes elevated triglyceride levels and low high-density lipoprotein cholesterol concentrations. Recent findings also showed that women with PCOS have qualitative LDL alterations, with increased levels of atherogenic small, dense LDL particles. Such lipid abnormalities constitute a common form of dyslipidemia, the so-called atherogenic lipoprotein phenotype (ALP), associated with a greater cardiovascular risk. Weight reduction and increased physical activity may constitute first-line therapy for ALP in PCOS, and lipid lowering drugs, particularly nicotinic acid and fibrates, should be used in patients with severe dyslipidemia. Statins have usually a lower impact on ALP, and their beneficial effect is often moderate. Insulin-sensitizing medications favorably alter each component of ALP and combined therapy with these agents remains an option; in particular, the combination pioglitazone plus metformin seems to be particularly beneficial.

Rizzo, M., Berneis, K., Carmina, E., Rini, G.B. (2008). How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome?. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 198(1), 28-e1-5 [10.1016/j.ajog.2007.09.014.].

How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome?

RIZZO, Manfredi;CARMINA, Enrico;RINI, Giovam Battista
2008-01-01

Abstract

Despite their young age, women with polycystic ovary syndrome (PCOS) have increased cardiovascular risk. Besides normal concentrations of low-density lipoprotein (LDL) cholesterol, dyslipidemia is very common and includes elevated triglyceride levels and low high-density lipoprotein cholesterol concentrations. Recent findings also showed that women with PCOS have qualitative LDL alterations, with increased levels of atherogenic small, dense LDL particles. Such lipid abnormalities constitute a common form of dyslipidemia, the so-called atherogenic lipoprotein phenotype (ALP), associated with a greater cardiovascular risk. Weight reduction and increased physical activity may constitute first-line therapy for ALP in PCOS, and lipid lowering drugs, particularly nicotinic acid and fibrates, should be used in patients with severe dyslipidemia. Statins have usually a lower impact on ALP, and their beneficial effect is often moderate. Insulin-sensitizing medications favorably alter each component of ALP and combined therapy with these agents remains an option; in particular, the combination pioglitazone plus metformin seems to be particularly beneficial.
2008
Settore MED/09 - Medicina Interna
Settore MED/13 - Endocrinologia
Rizzo, M., Berneis, K., Carmina, E., Rini, G.B. (2008). How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome?. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 198(1), 28-e1-5 [10.1016/j.ajog.2007.09.014.].
File in questo prodotto:
File Dimensione Formato  
44 AJOG 2008.pdf

Solo gestori archvio

Dimensione 184.84 kB
Formato Adobe PDF
184.84 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/76531
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 20
social impact